Arrestins in the Cardiovascular System - Progress in Molecular Biology and Translational Science - page 321

and function in G a q-overexpressing mice. Proc Natl Acad Sci USA . 1999;96:
6400- 6405.
54. Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-
adrenergic receptor overexpression in mouse hearts: critical role for expression level.
Circulation . 2000;101:1707- 1714.
55. Bristow MR, Ginsburg R, Umans V, et al. b 1-and b 2-adrenergic-receptor subpopu-
lations in nonfailing and failing human ventricular myocardium: coupling of both
receptor subtypes to muscle contraction and selective b 1-receptor down-regulation
in heart failure. Circ Res . 1986;59:297- 309.
56. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and
b -adrenegic receptor density in failing human hearts. N Engl J Med . 1982;307:205- 211.
57. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors
and heart function. Nature . 2002;415:206- 212.
58. Nikolaev VO, Moshkov A, Lyon AR, et al. Beta2-adrenergic receptor redistribution in
heart failure changes cAMP compartmentation. Science . 2010;327:1653- 1657.
59. Lymperopoulos A. Beta-arrestin biased agonism/antagonism at cardiovascular seven
transmembrane-spanning receptors. Curr Pharm Des . 2012;18:192- 195.
60. Conner DA, Mathier MA, Mortensen RM, et al. Beta-arrestin1 knockout mice appear
normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ
Res . 1997;81:1021- 1026.
61. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science .

2003;300:1530- 1532.
62. Bristow MR. b -Adrenergic receptor blockade in chronic heart failure. Circulation .
2000;101:558- 569.
63. Packer M, BristowMR, Cohn JN, et al. The effect of carvedilol on morbidity and mor-
tality in patients with chronic heart failure. N Engl J Med . 1996;334:1349- 1355.
64. Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerg-
ing concepts and therapeutic perspectives. Adv Pharmacol . 2010;59:135- 163.
65. Breit A, Lagac´ M, Bouvier M. Hetero-oligomerization between beta2- and beta3-
adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional
properties. J Biol Chem . 2004;279:28756- 28765.
66. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activ-
ity is increased in hypertension. J Clin Invest . 1997;99:2087- 2093.
67. Belmonte SL, Blaxall BC. G protein coupled receptor kinases as therapeutic targets in
cardiovascular disease. Circ Res . 2011;109:309- 319.
68. de Foucart S, Champlain J, Nadeau R. Modulation by beta-adrenoceptors and angio-
tensin II receptors of splanchnic nerve evoked catecholamine release from the adrenal
medulla. Can J Physiol Pharmacol . 1991;69:1- 7.
69. Foucart S, Nadeau R, de Champlain J. Local modulation of adrenal catecholamines
release by beta-2 adrenoceptors in the anaesthetized dog. Naunyn Schmiedebergs Arch
Pharmacol . 1988;337:29- 34.
70. Billet S, Aguilar F, Baudry C, Clauser E. Role of angiotensin II AT1 receptor activation
in cardiovascular diseases. Kidney Int . 2008;74:1379- 1384.
71. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ.
Receptor-specific in vivo desensitization by the G protein-coupled receptor
kinase-5 in transgenic mice. Proc Natl Acad Sci USA . 1996;93:9954 - 9959.
72. Balmforth AJ, Shepherd FH, Warburton P, Ball SG. Evidence of an important and
direct role for protein kinase C in agonist-induced phosphorylation leading to desen-
sitization of the angiotensin AT1A receptor. Br J Pharmacol . 1997;122:1469- 1477.
73. Olivares-Reyes JA, Smith RD, Hunyady L, Shah BH, Catt KJ. Agonist-induced sig-
naling, desensitization, and internalization of a phosphorylation-deficient AT1A angio-
tensin receptor. J Biol Chem . 2001;276:37761- 37768.